Log in / Register

MGP Database

New search | Record Overview | Ontology/Pathway Information | Domain Information | UniProt Annotations | Related Proteins

MGP001167

UniProt Annotations

Entry Information

Gene Name	glucosidase, beta, acid
Protein Entry	GLCM_HUMAN
UniProt ID	P04062
Species	Human

Comments

Comment type	Description
Alternative Products	Event=Alternative splicing, Alternative initiation; Named isoforms=5; Name=Long; IsoId=P04062-1; Sequence=Displayed; Note=Has a 39 residue signal sequence. The upstream initiation site produces two to three times as much protein as does the downstream initiation codon.; Name=Short; IsoId=P04062-2; Sequence=VSP_018800; Note=Has a 19 residue signal sequence.; Name=3; IsoId=P04062-3; Sequence=VSP_025216, VSP_025217, VSP_025218; Note=Produced by alternative splicing.; Name=4; IsoId=P04062-4; Sequence=VSP_054655; Note=No experimental confirmation available.; Name=5; IsoId=P04062-5; Sequence=VSP_054656; Note=No experimental confirmation available.;
Catalytic Activity	D-glucosyl-N-acylsphingosine + H(2)O = D- glucose + N-acylsphingosine.
Disease	Gaucher disease 1 (GD1) [MIM:230800]: A form of Gaucher disease characterized by hepatosplenomegaly with consequent anemia and thrombopenia, and bone involvement. The central nervous system is not involved. {ECO:0000269\|PubMed:10206680, ECO:0000269\|PubMed:10340647, ECO:0000269\|PubMed:15605411, ECO:0000269\|PubMed:8889591, ECO:0000269\|Ref.14}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Disease	Gaucher disease 2 (GD2) [MIM:230900]: The most severe form of Gaucher disease. It manifests soon after birth, with death generally occurring before patients reach two years of age. {ECO:0000269\|PubMed:9637431, ECO:0000269\|PubMed:9851895}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Disease	Gaucher disease 3C (GD3C) [MIM:231005]: A variant of subacute neuronopathic Gaucher disease 3 associated with cardiovascular calcifications. Note=The disease is caused by mutations affecting the gene represented in this entry.
Disease	Gaucher disease 3 (GD3) [MIM:231000]: A subacute form of neuronopathic Gaucher disease. It has later onset and slower progression compared to the acute form of neuronopathic Gaucher disease 2. {ECO:0000269\|PubMed:8780099}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Disease	Gaucher disease (GD) [MIM:230800]: A lysosomal storage disease due to deficient activity of beta-glucocerebrosidase and characterized by accumulation of glucosylceramide in the reticulo- endothelial system. Different clinical forms are recognized depending on the presence (neuronopathic forms) or absence of central nervous system involvement, severity and age of onset. {ECO:0000269\|PubMed:10352942, ECO:0000269\|PubMed:10360404, ECO:0000269\|PubMed:10447266, ECO:0000269\|PubMed:10744424, ECO:0000269\|PubMed:10796875, ECO:0000269\|PubMed:11933202, ECO:0000269\|PubMed:11992489, ECO:0000269\|PubMed:12204005, ECO:0000269\|PubMed:15292921, ECO:0000269\|PubMed:1972019, ECO:0000269\|PubMed:1974409, ECO:0000269\|PubMed:7627184, ECO:0000269\|PubMed:7627192, ECO:0000269\|PubMed:7916532, ECO:0000269\|PubMed:8076951, ECO:0000269\|PubMed:8112750, ECO:0000269\|PubMed:8294033, ECO:0000269\|PubMed:8432537, ECO:0000269\|PubMed:8790604, ECO:0000269\|PubMed:8829654, ECO:0000269\|PubMed:8829663, ECO:0000269\|PubMed:8937765, ECO:0000269\|PubMed:9061570, ECO:0000269\|PubMed:9153297, ECO:0000269\|PubMed:9182788, ECO:0000269\|PubMed:9217217, ECO:0000269\|PubMed:9279145, ECO:0000269\|PubMed:9516376, ECO:0000269\|PubMed:9554454, ECO:0000269\|PubMed:9554746, ECO:0000269\|PubMed:9650766, ECO:0000269\|PubMed:9683600}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Disease	Gaucher disease perinatal lethal (GDPL) [MIM:608013]: Distinct form of Gaucher disease type 2, characterized by fetal onset. Hydrops fetalis, in utero fetal death and neonatal distress are prominent features. When hydrops is absent, neurologic involvement begins in the first week and leads to death within 3 months. Hepatosplenomegaly is a major sign, and is associated with ichthyosis, arthrogryposis, and facial dysmorphism. Note=The disease is caused by mutations affecting the gene represented in this entry.
Disease	Note=Perinatal lethal Gaucher disease is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders.
Disease	Parkinson disease (PARK) [MIM:168600]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features. {ECO:0000269\|PubMed:12847165, ECO:0000269\|PubMed:16148263, ECO:0000269\|PubMed:19286695}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.
Enzyme Regulation	Requires saposin-C and anionic phospholipids for activity.
Interaction	O35114:Scarb2 (xeno); NbExp=1; IntAct=EBI-1564609, EBI-1564519;
Pharmaceutical	Available under the names Ceredase and Cerezyme (Genzyme). Used to treat Gaucher's disease.
Similarity	Belongs to the glycosyl hydrolase 30 family. {ECO:0000305}.
Subcellular Location	Lysosome membrane {ECO:0000269\|PubMed:17187079, ECO:0000269\|PubMed:17897319, ECO:0000269\|PubMed:18022370}; Peripheral membrane protein {ECO:0000269\|PubMed:17187079, ECO:0000269\|PubMed:17897319, ECO:0000269\|PubMed:18022370}; Lumenal side {ECO:0000269\|PubMed:17187079, ECO:0000269\|PubMed:17897319, ECO:0000269\|PubMed:18022370}. Note=Interaction with saposin-C promotes membrane association. Targeting to lysosomes occurs through an alternative MPR-independent mechanism via SCARB2.
Subunit	Interacts with saposin-C. Interacts with SCARB2. {ECO:0000269\|PubMed:10781797, ECO:0000269\|PubMed:15817452, ECO:0000269\|PubMed:18022370}.
Web Resource	Name=Ceredase; Note=Clinical information on Ceredase; URL="http://www.rxlist.com/ceredase-drug.htm";
Web Resource	Name=Cerezyme; Note=Clinical information on Cerezyme; URL="http://www.rxlist.com/cerezyme-drug.htm";